Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk <scp><i>TP53</i></scp> disrupted B prolymphocytic leukaemia

Chen, Lucia; Eyre, Toby A.

doi:10.1111/ejh.13837

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, the sequential consolidation and maintenance therapies of ibrutinib or an anti-CD20 monoclonal antibody monotherapy or combination therapy may further deepen remission and improve survival. Also, venetoclax monotherapy has been demonstrated to be efficacious in patients with relapsed/refractory B-PLL ( 24 ). Further treatment with allogeneic hematopoietic stem cell transplantation (Allo-HSCT) could also be considered as a first-line treatment in young responders and is the only current treatment that is likely capable of curing B-PLL patients ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases

Guo¹,

Damiani²,

Sumbly³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell tumor with an aggressive clinical course and poor prognosis. It is characterized by prominent splenomegaly and prolymphocytes exceeding 55% of the lymphoid cells in the blood. Purine analog-based chemo-immunotherapy is the first-line therapy for B-PLL. Owing to its rarity, there are few reports on the efficacy of bendamustine and rituximab (BR) regimen. Our study presents three cases of BR being effective in the treatment of B-PLL and provides experience for clinical treatment. Case Description This report describes the cases of three male patients (median age: 66 years old) who initially presented with abdominal discomfort. Physical examinations and imaging revealed splenomegaly, while a peripheral blood (PB) smear revealed a prolymphocyte count exceeding 70% of the lymphoid cells. Therefore, the three patients were diagnosed with B-PLL. Further molecular detection showed that they harbored P53 abnormalities (17p deletion/ TP53 mutation) associated with resistance to conventional chemotherapies. In addition, one of the patients had a highly complex karyotype and multiple gene mutations. All patients underwent four cycles of BR, and two of them received two further cycles of rituximab monotherapy. Ultimately, the patients achieved a complete response (CR) that lasted for 25, 33, and 34 months, respectively, with a median follow-up time of 34 months. The adverse events of the BR mainly included a grade 3 haematological toxicities. Also, the treatment was well-tolerated. Conclusions This case series suggests that BR regimen is promising for bringing deep remission to patients with B-PLL. Prospective trials are still required for further elucidation.

show abstract

Section: Discussionmentioning

confidence: 99%